全身免疫炎症指数联合预后营养指数对接受根治性切除术的肝细胞癌的预后价值研究

doi:10.3877/cma.j.issn.1674-0793.2023.02.002

目的

探讨联合全身免疫炎症指数（SII）与预后营养指数（PNI）对接受根治性切除术的肝细胞癌患者预后的预测价值。

方法

收集2016年10月至2017年9月蚌埠医学院第一附属医院144例行肝细胞癌根治术的患者临床病理资料与随访信息。使用受试者工作特征（ROC）曲线计算SII和PNI的截断值，并依此将患者分为高SII组、低SII组、高PNI组、低PNI组。分析不同SII、PNI分组与临床病理资料之间的关系，通过单因素和Cox多因素回归模型分析探讨与患者手术预后相关的因素。根据SII和PNI表达水平，将患者分为低SII高PNI组、高SII低PNI组，并将高SII高PNI患者和低SII低PNI患者纳入同一组中。采用Kaplan-Meier曲线进行术后1、3、5年生存分析，ROC曲线评估SII、PNI以及SII+PNI对患者手术预后的预测效能。

结果

SII的曲线下面积（AUC）为0.778，对应截断值为301.48。PNI的AUC为0.721，对应截断值为47.60。通过对不同组别进行分析表明，SII与肝硬化、甲胎蛋白（AFP）水平、TNM分期和肿瘤直径相关（P<0.05），PNI与年龄、AFP水平、TNM分期、肿瘤直径相关（P<0.05）。多因素分析表明，HBsAg、AFP水平、TNM分期、SII和PNI是患者术后生存的相关因素。生存分析显示，低SII组、高PNI组患者术后1、3、5年生存率分别优于高SII组和低PNI组患者（均P<0.05）；相较于高SII低PNI组、高SII高PNI组和低SII低PNI组患者，低SII高PNI组患者术后1、3、5年生存率更高（P<0.05）。SII+PNI联合判断患者预后的AUC为0.840，高于SII和PNI。

结论

SII和PNI均可预测肝细胞癌手术患者的预后，并且相较于单一指标，联合SII和PNI可获得更准确的预测结果。

关键词: 肝细胞癌, 全身免疫炎症指数, 预后营养指数, 预后

Objective

To explore the prognostic value of combined systemic immune inflammatory index (SII) and prognostic nutritional index (PNI) in patients with hepatocellular carcinoma (HCC) undergoing radical resection.

Methods

From October 2016 to September 2017, the clinicopathological data and follow-up information of 144 patients who underwent HCC radical resection in the First Affiliated Hospital of Bengbu Medical College were collected. The receiver operator characteristics (ROC) curve was used to calculate the cut-off values of SII and PNI, and the patients were divided into high SII group, low SII group, high PNI group, and low PNI group. The relationship between different SII and PNI groups and clinical pathological data were analyzed, and the factors related to the prognosis of patients were analyzed by univariate and Cox multivariate regression models. According to the expression level of SII and PNI, patients were divided into low SII+high PNI group, high SII+low PNI group, and patients with high SII+high PNI or low SII+low PNI were included in the other group. Kaplan-Meier curve was used to analyze the 1-, 3-, and 5-year survival after surgery, and ROC curves were used to evaluate the predictive efficacy of SII, PNI, and SII+PNI on the prognosis of patients after surgery.

Results

The area under curve (AUC) of SII was 0.778, and the corresponding cut-off value was 301.48. The AUC of PNI was 0.721, and the corresponding truncation value was 47.60. SII was correlated with cirrhosis, AFP level, TNM staging and tumor diameter (P<0.05), and PNI was correlated with age, AFP level, TNM staging and tumor diameter (P<0.05). Multivariate analysis showed that HBsAg, AFP level, TNM staging, SII and PNI were related to the prognosis. The 1-, 3- and 5-year survival rates of patients in the low SII group and high PNI group were better than those in the high SII group and low PNI group respectively (all P<0.05). Compared with patients with high SII+low PNI, high SII+high PNI and low SII+low PNI, the patients with low SII+high PNI had higher survival rate (P<0.05). ROC curve showed that AUC of SII+PNI was 0.840, higher than SII and PNI.

Conclusion

Both SII and PNI can predict the prognosis of HCC patients after curative resection, and the combination of SII and PNI can obtain more accurate prediction results than any single index.

Key words: Hepatocellular carcinoma, Systemic immunoinflammatory index, Prognostic nutritional index, Prognosis

表1 SII、PNI与肝细胞癌患者临床病理特征的关系(例)

临床病理特征	低SII组	高SII组	χ²值	P值	低PNI组	高PNI组	χ²值	P值
例数	59	85			97	47
年龄(岁)			0.359	0.549			25.326	<0.001^a
<60	43	58			64	10
≥60	16	27			33	37
性别(男/女)			0.083	0.774			0.489	0.484
男	49	69			81	37
女	10	16			16	10
HbsAg			0.783	0.376			1.579	0.209
阴性	10	10			13	3
阳性	49	75			84	44
肝硬化			8.031	0.005^a			0.017	0.895
无	31	64			63	30
有	28	21			34	17
AFP(μg/L)			4.364	0.037^a			6.099	0.014^a
<200	39	54			58	35
≥200	20	31			39	12
Child-Pugh分级			0.105	0.746			0.156	0.693
A	55	78			89	44
B	4	7			8	3
局部侵犯			1.737	0.187			0.063	0.803
无	43	53			66	31
有	16	32			31	16
淋巴结转移			0.468	0.485			0.376	0.473
无	2	3			4	1
有	57	82			93	46
TNM分期			8.539	0.014^a			18.198	<0.001^a
Ⅰ~Ⅱ	52	60			71	40
Ⅲ	7	25			26	7
肿瘤数目(个)			0.397	0.528			0.923	0.337
<2	49	67			76	40
≥2	10	18			21	7
肿瘤直径(cm)			4.419	0.042^a			9.206	0.014^a
<5	14	34			32	28
≥5	45	51			65	19

表1 SII、PNI与肝细胞癌患者临床病理特征的关系(例)

临床病理特征	低SII组	高SII组	χ²值	P值	低PNI组	高PNI组	χ²值	P值
例数	59	85			97	47
年龄(岁)			0.359	0.549			25.326	<0.001^a
<60	43	58			64	10
≥60	16	27			33	37
性别(男/女)			0.083	0.774			0.489	0.484
男	49	69			81	37
女	10	16			16	10
HbsAg			0.783	0.376			1.579	0.209
阴性	10	10			13	3
阳性	49	75			84	44
肝硬化			8.031	0.005^a			0.017	0.895
无	31	64			63	30
有	28	21			34	17
AFP(μg/L)			4.364	0.037^a			6.099	0.014^a
<200	39	54			58	35
≥200	20	31			39	12
Child-Pugh分级			0.105	0.746			0.156	0.693
A	55	78			89	44
B	4	7			8	3
局部侵犯			1.737	0.187			0.063	0.803
无	43	53			66	31
有	16	32			31	16
淋巴结转移			0.468	0.485			0.376	0.473
无	2	3			4	1
有	57	82			93	46
TNM分期			8.539	0.014^a			18.198	<0.001^a
Ⅰ~Ⅱ	52	60			71	40
Ⅲ	7	25			26	7
肿瘤数目(个)			0.397	0.528			0.923	0.337
<2	49	67			76	40
≥2	10	18			21	7
肿瘤直径(cm)			4.419	0.042^a			9.206	0.014^a
<5	14	34			32	28
≥5	45	51			65	19

图1 全身免疫炎症指数（SII）和预后营养指数（PNI）的ROC曲线　A为SII；B为PNI

表2 肝细胞癌患者预后相关因素的单因素与多因素分析

临床病理特征	单因素分析				多因素分析
临床病理特征	SE	HR	95% CI	P值	β	SE	Wald	HR	95% CI	P值
年龄(岁, <60/≥60)	0.240	1.620	1.012~2.592	0.044	-0.450	0.266	2.866	0.637	0.378~1.074	0.090
性别(男/女)	0.297	1.178	0.658~2.108	0.581	-	-	-		-	-
HBsAg(-/+)	0.271	1.947	1.217~3.115	0.005	0.765	0.270	8.045	2.150	1.267~3.648	0.005^a
肝硬化(无/有)	0.251	1.126	0.688~1.843	0.638	-	-	-		-	-
AFP(μg/L, <200/≥200)	0.233	0.573	0.363~0.906	0.037	-0.642	0.244	6.940	0.526	0.327~0.849	0.008^a
局部侵犯(无/有)	0.256	0.849	0.528~1.365	0.499	-	-	-		-	-
淋巴结转移(无/有)	0.518	0.319	0.116~0.881	0.027	-0.247	0.560	0.195	0.781	0.260~2.342	0.695
TNM分期(Ⅰ~Ⅱ/Ⅲ)	0.315	0.498	0.268~0.604	0.017	-0.605	0.283	4.567	0.546	0.313~0.951	-0.032^a
肿瘤数目(个, <2/≥2)	0.271	0.696	0.409~1.184	0.181	-	-	-		-	-
肿瘤直径(cm, < 5/≥5)	0.024	1.135	1.083~1.188	<0.001	0.056	0.031	3.325	1.058	0.996~1.123	0.068
SII	0.236	0.419	0.264~0.666	<0.001	-1.029	2.720	13.212	0.357	0.205~0.622	<0.001^a
PNI	0.242	1.635	1.018~2.626	0.042	0.642	0.364	5.886	1.900	1.131~3.190	0.015^a

表2 肝细胞癌患者预后相关因素的单因素与多因素分析

临床病理特征	单因素分析				多因素分析
临床病理特征	SE	HR	95% CI	P值	β	SE	Wald	HR	95% CI	P值
年龄(岁, <60/≥60)	0.240	1.620	1.012~2.592	0.044	-0.450	0.266	2.866	0.637	0.378~1.074	0.090
性别(男/女)	0.297	1.178	0.658~2.108	0.581	-	-	-		-	-
HBsAg(-/+)	0.271	1.947	1.217~3.115	0.005	0.765	0.270	8.045	2.150	1.267~3.648	0.005^a
肝硬化(无/有)	0.251	1.126	0.688~1.843	0.638	-	-	-		-	-
AFP(μg/L, <200/≥200)	0.233	0.573	0.363~0.906	0.037	-0.642	0.244	6.940	0.526	0.327~0.849	0.008^a
局部侵犯(无/有)	0.256	0.849	0.528~1.365	0.499	-	-	-		-	-
淋巴结转移(无/有)	0.518	0.319	0.116~0.881	0.027	-0.247	0.560	0.195	0.781	0.260~2.342	0.695
TNM分期(Ⅰ~Ⅱ/Ⅲ)	0.315	0.498	0.268~0.604	0.017	-0.605	0.283	4.567	0.546	0.313~0.951	-0.032^a
肿瘤数目(个, <2/≥2)	0.271	0.696	0.409~1.184	0.181	-	-	-		-	-
肿瘤直径(cm, < 5/≥5)	0.024	1.135	1.083~1.188	<0.001	0.056	0.031	3.325	1.058	0.996~1.123	0.068
SII	0.236	0.419	0.264~0.666	<0.001	-1.029	2.720	13.212	0.357	0.205~0.622	<0.001^a
PNI	0.242	1.635	1.018~2.626	0.042	0.642	0.364	5.886	1.900	1.131~3.190	0.015^a

图2 不同全身免疫炎症指数（SII）、预后营养指数（PNI）分组肝细胞癌患者术后5年生存曲线　A为高SII组vs低SII组；B为高PNI组vs低PNI组；C为低SII高PNI组、高SII低PNI组和低SII低PNI/高SII高PNI组比较

图3 全身免疫炎症指数（SII）、预后营养指数（PNI）单独和联合检测对肝细胞癌患者预后的预测效能比较

[1]	国家癌症中心, 国家肿瘤质控中心肝癌质控专家委员会. 中国肝癌规范诊疗质量控制指标(2022版)[J]. 中华肿瘤杂志, 2022, 44(7): 600-608.
[2]	Liu J, Gao D, Li J, et al. The predictive value of systemic inflammatory factors in advanced, metastatic esophageal squamous cell carcinoma patients treated with camrelizumab[J]. Onco Targets Ther, 2022, 15: 1161-1170.
[3]	Xu S, Cao S, Geng J, et al. High prognostic nutritional index (PNI) as a positive prognostic indicator for non-small cell lung cancer patients with bone metastasis[J]. Clin Respir J, 2021, 15(2): 225-231.
[4]	Ding P, Guo H, Sun C, et al. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective study[J]. BMC Gastroenterol, 2022, 22(1): 121.
[5]	Liu T, Ye F, Li Y, et al. Comparison and exploration of the prognostic value of the advanced lung cancer inflammation index, prognostic nutritional index, and systemic immune-inflammation index in newly diagnosed diffuse large B-cell lymphoma[J]. Ann Palliat Med, 2021, 10(9): 9650-9659.
[6]	Wang YY, Zhou N, Liu HS, et al. Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression[J]. Cancer Med, 2020, 9(14): 5086-5094.
[7]	Xiao Y, Cong M, Li J, et al. Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation[J]. Cancer Cell, 2021, 39(3): 423-437, e7.
[8]	Zhao LY, Yang DD, Ma XK, et al. The prognostic value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for overall survival of hepatocellular carcinoma patients treated with palliative treatments[J]. J Cancer, 2019, 10(10): 2299-2311.
[9]	Hong YM, Yoon KT, Cho M. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma[J]. BMC Cancer, 2021, 21(1): 569.
[10]	Wang BL, Tian L, Gao XH, et al. Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection[J]. Clin Chem Lab Med, 2016, 54(12): 1963-1969.
[11]	傅宇翔, 潘凯, 夏利刚, 等. 预后营养指数对结直肠癌同时性肝转移患者预后评估的价值[J/CD]. 中华普通外科学文献(电子版), 2021, 15(4): 273-277.
[12]	Mei J, Sun XQ, Lin WP, et al. Comparison of the prognostic value of inflammation-based scores in patients with hepatocellular carcinoma after anti-PD-1 therapy[J]. J Inflamm Res, 2021, 14: 3879-3890.
[13]	Imai D, Maeda T, Shimokawa M, et al. Prognostic nutritional index is superior as a predictor of prognosis among various inflammation-based prognostic scores in patients with hepatocellular carcinoma after curative resection[J]. Hepatol Res, 2020, 50(1): 101-109.
[14]	Oh SE, Choi MG, Seo JM, et al. Prognostic significance of perioperative nutritional parameters in patients with gastric cancer[J]. Clin Nutr, 2019, 38(2): 870-876.
[15]	Lin JX, Lin JP, Xie JW, et al. Prognostic value and association of sarcopenia and systemic inflammation for patients with gastric cancer following radical gastrectomy[J]. Oncologist, 2019, 24(11): e1091-1091, e1101.
[16]	Zhao WY, Zhang Y, Hou LS, et al. The association between systemic inflammatory markers and sarcopenia: results from the West China Health and Aging Trend Study (WCHAT)[J]. Arch Gerontol Geriatr, 2021, 92: 104262.
[17]	Migita K, Matsumoto S, Wakatsuki K, et al. Effect of oral nutritional supplementation on the prognostic nutritional index in gastric cancer patients[J]. Nutr Cancer, 2021, 73(11-12): 2420-2427.

[1]	史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(08): 778-784.
[2]	许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4]	李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5]	李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[6]	关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[7]	张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[8]	韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[9]	刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[10]	陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[11]	曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[12]	沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[13]	王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[14]	王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[15]	郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Predictive value of combined systemic immunoinflammatory index and prognostic nutritional index on the prognosis of patients with hepatocellular carcinoma after radical resection

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Predictive value of combined systemic immunoinflammatory index and prognostic nutritional index on the prognosis of patients with hepatocellular carcinoma after radical resection